Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AVNS NASDAQ:ESTA NASDAQ:INGN NYSE:IVC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVNSAVANOS MEDICAL$12.52+2.5%$11.63$9.30▼$25.36$580.93M1.12538,344 shs114,390 shsESTAEstablishment Labs$37.24-0.6%$40.85$26.56▼$50.85$1.08B0.85504,490 shs41,978 shsINGNInogen$8.64+1.1%$7.27$5.70▼$12.91$233.36M1.78271,215 shs25,396 shsIVCInvacare$0.50$0.33▼$2.53$20.01M0.38240,305 shs33,301 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVNSAVANOS MEDICAL0.00%-3.73%+9.39%+0.05%-49.04%ESTAEstablishment Labs0.00%-4.00%-2.22%-3.70%-15.23%INGNInogen0.00%+5.30%+14.48%+29.39%-24.62%IVCInvacare0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVNSAVANOS MEDICAL$12.52+2.5%$11.63$9.30▼$25.36$580.93M1.12538,344 shs114,390 shsESTAEstablishment Labs$37.24-0.6%$40.85$26.56▼$50.85$1.08B0.85504,490 shs41,978 shsINGNInogen$8.64+1.1%$7.27$5.70▼$12.91$233.36M1.78271,215 shs25,396 shsIVCInvacare$0.50$0.33▼$2.53$20.01M0.38240,305 shs33,301 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVNSAVANOS MEDICAL0.00%-3.73%+9.39%+0.05%-49.04%ESTAEstablishment Labs0.00%-4.00%-2.22%-3.70%-15.23%INGNInogen0.00%+5.30%+14.48%+29.39%-24.62%IVCInvacare0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVNSAVANOS MEDICAL 2.00HoldN/AN/AESTAEstablishment Labs 2.83Moderate Buy$56.5049.75% UpsideINGNInogen 2.50Moderate Buy$11.0028.35% UpsideIVCInvacare 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest INGN, AVNS, ESTA, and IVC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025ESTAEstablishment LabsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.008/12/2025AVNSAVANOS MEDICALZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/16/2025ESTAEstablishment LabsMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$58.00 ➝ $70.007/9/2025ESTAEstablishment LabsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$38.00 ➝ $47.006/16/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/15/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVNSAVANOS MEDICAL$687.80M0.83$12.00 per share1.03$18.03 per share0.69ESTAEstablishment Labs$166.02M6.58N/AN/A$1.90 per share19.86INGNInogen$343.47M0.67N/AN/A$7.30 per share1.17IVCInvacare$872.46M0.00N/A0.77$5.54 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVNSAVANOS MEDICAL-$392.10M-$10.07N/A7.15N/A-66.89%6.16%4.57%10/29/2025 (Estimated)ESTAEstablishment Labs-$84.60M-$3.05N/AN/AN/A-49.89%-224.34%-25.53%11/6/2025 (Estimated)INGNInogen-$35.89M-$1.06N/AN/AN/A-7.58%-13.77%-8.52%11/6/2025 (Estimated)IVCInvacare-$45.56M-$2.18N/AN/AN/A-9.99%-37.76%-7.18%N/ALatest INGN, AVNS, ESTA, and IVC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ESTAEstablishment Labs-$0.54-$0.57-$0.03-$0.57$50.80 million$51.30 million8/7/2025Q2 2025INGNInogen-$0.22-$0.15+$0.07-$0.15$90.40 million$92.28 million8/5/2025Q2 2025AVNSAVANOS MEDICAL$0.18$0.17-$0.01-$1.66$165.50 million$175.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVNSAVANOS MEDICALN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/AIVCInvacareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVNSAVANOS MEDICAL0.122.641.58ESTAEstablishment Labs9.712.841.67INGNInogenN/A3.032.67IVCInvacare4.821.320.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVNSAVANOS MEDICAL95.17%ESTAEstablishment Labs72.91%INGNInogen89.94%IVCInvacare59.87%Insider OwnershipCompanyInsider OwnershipAVNSAVANOS MEDICAL2.64%ESTAEstablishment Labs11.44%INGNInogen1.46%IVCInvacare6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVNSAVANOS MEDICAL2,22746.40 million45.18 millionOptionableESTAEstablishment Labs1,01828.97 million25.66 millionOptionableINGNInogen1,03027.04 million26.65 millionOptionableIVCInvacare3,00037.76 million35.15 millionOptionableINGN, AVNS, ESTA, and IVC HeadlinesRecent News About These CompaniesRhône in talks to buy, combine Invacare Holdings & Direct Healthcare GroupJuly 8, 2025 | hmenews.comHPrivate equity firm eyes up majority shareholding of Invacare and Direct Healthcare GroupJuly 8, 2025 | thiis.co.ukTRhône in talks to acquire Direct Healthcare Group and InvacareJuly 8, 2025 | pehub.comInvacare America partnership creates ‘on-chair’ solutionJune 17, 2025 | hmenews.comHInvacare unveils innovative limited edition wooden wheelchair at Autonomic Paris 2025June 11, 2025 | thiis.co.ukTInvacare partners with charity legend to fundraise for wheelchairs in remote communitiesMay 27, 2025 | thiis.co.ukTInvacare tees up second ‘Move For Mobility’ campaignApril 30, 2025 | hmenews.comHImplantable Vena Cava Sensor Successful in First Human StudyApril 17, 2025 | medscape.comMVets say they are under pressure to bring in more money per petApril 15, 2025 | msn.comA Heavy duty star from IVC CommercialApril 14, 2025 | specificationonline.co.ukSIVC issues threat to independent veterinary practicesMarch 12, 2025 | vetsurgeon.orgVInvacare to relocate some jobsJanuary 13, 2025 | hmenews.comHInvacare’s new owner in North America excels in turnaroundsNovember 22, 2024 | hmenews.comHInvacare sells NA businessNovember 11, 2024 | hmenews.comHIVC Filter Use Declining, but Retrieval Rates Abysmally Low: SAFE-IVCNovember 11, 2024 | tctmd.comTOHSAA football playoffs: Here are the matchups for the second roundNovember 6, 2024 | timesreporter.comTInvacare wins award for ‘Move’ campaignOctober 7, 2024 | hmenews.comHBuckeye Trail volleyball stays perfect with key IVC victorySeptember 6, 2024 | sports.yahoo.comInvacare partners with Marvel for accessible Superhero triathlon event in BerkshireAugust 22, 2024 | thiis.co.ukTInvacare reorganizes in North AmericaMay 3, 2024 | hmenews.comHMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025With Rate Cuts Ahead, Buffett-Backed Builders Look Like a BuyBy Jordan Chussler | September 4, 20253 Stocks Poised to Gain from a September Rate CutBy Chris Markoch | September 4, 2025INGN, AVNS, ESTA, and IVC Company DescriptionsAVANOS MEDICAL NYSE:AVNS$12.52 +0.30 (+2.46%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Establishment Labs NASDAQ:ESTA$37.24 -0.24 (-0.63%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.Inogen NASDAQ:INGN$8.64 +0.10 (+1.11%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.Invacare NYSE:IVCInvacare Corp. engages in the manufacture and distribution of medical equipment used in non-acute care settings. It focuses on medical device solutions for congenital, acquired, and degenerative ailments. The firm operates through the following segments: North America and Europe. The company was founded by Aaron Malachi Mixon III in 1979 and is headquartered in Elyria, OH. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
